Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery

Official Title

SYM-08-001: A Pilot Study to Evaluate the Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With Dilated Cardiomyopathy Undergoing Open-heart Surgery

Brief Summary

      This is a pilot study to evaluate the feasibility and safety of the Algisyl-LVR™ device. The
      purpose of this study is to investigate Algisyl-LVR™ employed as a method of left ventricular
      restoration in patients with dilated cardiomyopathy who are scheduled to undergo routine open
      heart surgery. Algisyl-LVR™ will be injected into the myocardium under direct visualization
      during the surgical procedure. This clinical evaluation is intended to provide the initial
      evidence of the safety and feasibility of the device as well as the procedure used to deploy
      the device. The results of the initial trial will also help to establish the utility of
      various assessments in evaluating and following the effects of the device.

Detailed Description

      Heart Failure (HF) is a progressive condition that has diverse etiologies with only 50
      percent of patients presenting at diagnosis with a defined reason for developing the disease.
      However, estimates are that over half of all patients presenting with HF have coronary artery
      disease (CAD) as the primary etiology. The most common etiologies among HF patients without
      CAD have been reported to be systemic hypertension and valvular disease. Irrespective of the
      etiology, the majority of patients with HF have symptoms due to an impairment of left
      ventricular (LV) myocardial function. HF is a progressive condition that results from
      myocardial damage. This damage can be caused by predisposing conditions or an acute event
      that leads to cardiac remodeling. The principal manifestation of such progression and cardiac
      remodeling is a change in the geometry and structure of the left ventricle (LV), such that
      the chamber dilates and/or hypertrophies and becomes more spherical. The cardiac remodeling
      is maladaptive and its progression leads to worsening of the clinical symptoms of HF,
      characterized by limited exercise tolerance and edema. Despite optimal medical management, HF
      is progressive in nature and patients have a mortality rate of over 50 percent in 5 years.

      Structural heart abnormalities are known to play a central role in HF, and clinical evidence
      supports a strong causal relationship between cardiac chamber dilation and heart failure.
      Because dilation, and not contractile dysfunction, appears to be responsible for the severity
      of the disease, the mitigation or prevention of the deleterious dilation process appears to
      be an important therapeutic target for HF patients. Hence, a therapy that specifically
      targets progressive LV dilatation and remodeling by reshaping and reducing the LV chamber
      size may offer an important new alternative in the treatment of HF.

      Algisyl-LVR™ is a single use, multiple component device under development for the indication
      to prevent or reverse the progression of heart failure (HF) by providing implanted
      space-occupying material in the myocardium to affect LV shape and prevent or reverse LV
      enlargement. The intended clinical benefits of Algisyl-LVR™ are to improve the failing
      heart's structure and function with an associated improvement in the patient's clinical
      status and quality of life. Data from this current study will be used to evaluate the initial
      feasibility of this novel therapeutic device.

      The objective of this pilot study is to evaluate the feasibility and safety of the
      Algisyl-LVR™ device. No formal hypothesis testing will be performed. Descriptive statistics
      will be used to summarize operator (surgeon) experience and patient outcomes. The results of
      the study will be used to assess the design of the device and feasibility of the procedures
      to use the device. The study will also guide the design and sample size of future studies.

      This study will be conducted at a several centers in Europe. The surgeon's experience with
      the use of the device will be collected and evaluated. Measures of safety and tolerability of
      Algisyl-LVR™ will be evaluated through analysis of adverse experiences, clinical laboratory
      tests, electrocardiograms, physical examinations, echocardiographic measures and magnetic
      resonance imaging (MRI). Measurements at specified time intervals will be compared to
      baseline values obtained prior to treatment.

      Patients will be evaluated prior to the procedure, during the immediate post operative
      period, and then, return to the clinic at 8 days, 3 months, 6 months, 12 months, 18 months
      and 24 months after the procedure for follow-up evaluations.

Study Phase

Phase 2

Study Type


Primary Outcome

Freedom from serious adverse events


Dilated Cardiomyopathy



Study Arms / Comparison Groups

 Algisyl-LVR implants
Description:  Algisyl-LVR implants to the left ventricular wall


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

February 2009

Completion Date

November 2012

Primary Completion Date

November 2011

Eligibility Criteria

        Inclusion Criteria

          1. The patients must be able and willing to give written informed consent.

          2. The patients will be adult (age ≥ 18 years and  2.0 mg/dL..

         11. Clinically significant liver enzyme abnormalities, i.e., AST or ALT more than two
             times the upper limit of normal and/or bilirubin more than 50% above the upper limit
             of normal.

         12. The patients will not be receiving concurrently an investigational Product in another
             clinical trial or have received an investigational Product in another clinical trial
             in the 30 days prior to enrollment.

         13. A life expectancy of less than 1 year or any other condition that, in the opinion of
             the clinical investigator, might compromise any aspect of the trial.




18 Years - 75 Years

Accepts Healthy Volunteers



Klaus Matschke, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

LoneStar Heart, Inc.

Study Sponsor

Klaus Matschke, MD, Principal Investigator, Heart Center Dresden University Hospital

Verification Date

November 2012